Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › LA › Raceland › NPI 1396761805
Hospital

Ochsner Bayou LLC

Ochsner Bayou LLC was paid $29.19M by Medicaid between Jan 2018 and Dec 2024, across 192 billing codes. Its largest line is 99284, emergency room visit (serious) — 32% of everything it billed.

33Billing provider infoOCHSNER BAYOU LLC
RACELAND, LA 70394
33aNPI1396761805assigned 07/15/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$29.19M
24GClaims557,888
24DCodes billed192
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Psychiatric Hospital Unit providers in Louisiana

Rank by total paid#1 of 7
Median peer was paid$3.63M
This provider vs. median8.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201870,044$2.48M
201974,661$3.56M
202064,169$3.30M
202178,589$4.65M
202298,954$5.30M
2023101,634$5.77M
2024incomplete69,837$4.13M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 32% 35,390 32,172 $9.30M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 12% 14,056 12,622 $3.51M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 12% 20,824 19,307 $3.36M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 7.1% 60,717 52,977 $2.07M
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 3.8% 17,395 15,840 $1.11M
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 2.8% 20,940 17,637 $817K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 2.3% 17,164 15,578 $679K
70450 Computed tomography, head or brain; without contrast material 2.3% 3,384 3,030 $667K
71045 Radiologic examination, chest; single view 1.9% 8,142 7,376 $555K
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 1.5% 11,085 9,934 $431K
74177 Computed tomography, abdomen and pelvis; with contrast material 1.4% 1,079 979 $419K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.2% 7,632 6,468 $348K
180 more codes
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 1.2% 11,196 $340K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 1.1% 10,268 $311K
74176 Computed tomography, abdomen and pelvis; without contrast material 1.0% 928 $296K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 9,962 $276K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 2,550 $261K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 5,340 $248K
80053 Comprehensive metabolic panel <1% 30,634 $236K
71046 Radiologic examination, chest; 2 views <1% 3,116 $222K
81514 <1% 1,154 $220K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 487 $182K
96361 Intravenous infusion, hydration; each additional hour <1% 5,897 $181K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 30,056 $172K
96375 Therapeutic injection; each additional sequential IV push <1% 4,049 $161K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 2,506 $157K
74019 <1% 1,495 $134K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 2,607 $130K
83880 <1% 5,266 $126K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,730 $115K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 3,637 $110K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 3,650 $108K
36415 Collection of venous blood by venipuncture <1% 45,030 $106K
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring <1% 472 $97K
81025 <1% 12,147 $85K
84484 <1% 10,170 $78K
87634 <1% 1,147 $72K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 1,084 $69K
20610 <1% 236 $53K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 1,949 $52K
72100 <1% 751 $51K
87481 <1% 771 $50K
73564 <1% 530 $47K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 718 $45K
73630 <1% 562 $44K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 2,931 $41K
83690 <1% 7,484 $40K
82553 <1% 5,234 $40K
J0561 Injection, penicillin g benzathine, 100,000 units <1% 270 $40K
73130 <1% 452 $38K
84443 Thyroid stimulating hormone (TSH) <1% 3,119 $35K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 1,631 $34K
81000 <1% 11,227 $31K
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 2,930 $28K
80050 General health panel <1% 769 $28K
82550 <1% 6,571 $28K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 1,294 $27K
59025 Fetal non-stress test <1% 258 $26K
87040 <1% 3,664 $25K
87400 <1% 1,748 $25K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 6,588 $25K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 669 $22K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,554 $22K
73560 <1% 311 $22K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 43 $22K
80061 Lipid panel <1% 1,962 $20K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 776 $19K
87081 <1% 2,749 $19K
83605 <1% 2,550 $19K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 6,041 $15K
73610 <1% 195 $15K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 799 $15K
85379 <1% 2,031 $15K
81003 <1% 8,773 $14K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 2,638 $14K
73562 <1% 191 $13K
J2360 Injection, orphenadrine citrate, up to 60 mg <1% 720 $13K
73030 <1% 181 $12K
87807 <1% 908 $12K
80179 <1% 902 $11K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 513 $11K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) <1% 261 $10K
83036 Hemoglobin; glycosylated (A1C) <1% 1,246 $10K
87660 <1% 447 $9K
87510 <1% 432 $8K
87480 <1% 432 $8K
J2920 Injection, methylprednisolone sodium succinate, up to 40 mg <1% 955 $8K
72040 <1% 141 $8K
82607 <1% 769 $8K
82746 <1% 764 $8K
83735 <1% 1,587 $7K
99215 Doctor's office visit, returning patient (complex) <1% 129 $7K
85730 <1% 1,885 $7K
84439 <1% 1,087 $7K
77067 Screening mammography, bilateral, including computer-aided detection <1% 66 $6K
84145 <1% 396 $6K
86803 <1% 448 $6K
J2270 Injection, morphine sulfate, up to 10 mg <1% 1,993 $6K
71275 Computed tomographic angiography, chest, with contrast material <1% 17 $5K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 198 $5K
85610 <1% 1,995 $5K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 60 $5K
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 116 $5K
84100 <1% 1,450 $5K
0002A <1% 144 $5K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 30 $4K
J1170 Injection, hydromorphone, up to 4 mg <1% 941 $4K
76830 Ultrasound, transvaginal <1% 41 $4K
86703 <1% 345 $4K
90686 <1% 335 $4K
84702 <1% 273 $4K
87186 <1% 714 $3K
0001A <1% 135 $3K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 194 $3K
87077 <1% 699 $3K
87088 <1% 519 $3K
84481 <1% 379 $3K
J1030 Injection, methylprednisolone acetate, 40 mg <1% 296 $3K
80320 <1% 408 $3K
59430 <1% 19 $3K
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 627 $2K
72125 Computed tomography, cervical spine; without contrast material <1% 14 $2K
90715 <1% 90 $2K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 26 $2K
85027 <1% 402 $2K
80329 <1% 288 $2K
96160 <1% 114 $2K
84425 <1% 147 $2K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 13 $2K
J7030 Infusion, normal saline solution , 1000 cc <1% 519 $2K
80048 Basic metabolic panel (calcium, ionized) <1% 211 $1K
72170 <1% 39 $1K
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 304 $1K
76801 <1% 12 $1K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 15 $1K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 507 $1K
74018 <1% 12 $1K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 496 $1K
82962 <1% 324 $1K
77063 Screening digital breast tomosynthesis, bilateral <1% 66 $1K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 27 $916.27
80055 <1% 37 $878.02
86593 <1% 243 $864.66
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 13 $864.00
85007 <1% 341 $839.80
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 145 $830.01
J2060 Injection, lorazepam, 2 mg <1% 312 $826.58
87653 <1% 26 $820.05
94760 <1% 127 $816.03
82728 <1% 87 $788.96
96376 <1% 54 $743.85
0071A <1% 18 $688.17
J2550 Injection, promethazine hcl, up to 50 mg <1% 391 $638.80
J2175 Injection, meperidine hydrochloride, per 100 mg <1% 200 $603.49
86850 <1% 143 $574.03
83655 <1% 46 $549.05
86140 <1% 143 $520.11
85651 <1% 181 $506.61
0072A <1% 13 $498.94
J3490 Unclassified drugs <1% 92 $464.77
87147 <1% 66 $405.66
J7120 Ringers lactate infusion, up to 1000 cc <1% 100 $325.15
83615 <1% 72 $324.68
84144 <1% 15 $310.11
82950 <1% 70 $284.15
86901 <1% 128 $278.63
86900 <1% 128 $278.62
84466 <1% 26 $271.16
87340 <1% 30 $244.48
90833 Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) <1% 24 $220.51
86308 <1% 48 $217.93
86762 <1% 12 $174.85
90656 <1% 44 $158.25
J1040 Injection, methylprednisolone acetate, 80 mg <1% 12 $142.29
83540 <1% 26 $137.47
81002 <1% 37 $123.21
99459 <1% 197 $113.36
0352U <1% 112 $89.50
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 43 $79.96
82803 <1% 12 $57.92
81001 <1% 13 $56.11
82043 <1% 12 $46.77
82570 <1% 12 $41.90
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml <1% 12 $41.83
91300 <1% 329 $5.62
G0463 Hospital outpatient clinic visit for assessment and management of a patient 0% 3,469 $0.00
G0008 Administration of influenza virus vaccine 0% 17 $0.00
99309 Subsequent nursing facility care, per day, low to moderate complexity 0% 77 $0.00
91307 0% 45 $0.00
99308 Subsequent nursing facility care, per day, straightforward 0% 40 $0.00
99490 Ccm add 20min 0% 660 $0.00
Q0244 Injection, casirivimab and imdevimab, 1200 mg 0% 210 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLEBLANC, FERNIS (CEO)
Same official

Other billing entities under LEBLANC, FERNIS

Full network →
ProviderLocationPaid
Ochsner Morgan City LLCMorgan City, LA$10.29M
Ochsner Bayou, LLCRaceland, LA$3K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.